8-K: Dare Bioscience Reports Positive Interim Phase 3 Results for Novel Hormone-Free Contraceptive Ovaprene

Dare Bioscience, Inc. announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial for Ovaprene, its investigational monthly, hormone-free intravaginal contraceptive, with the Data Safety Monitoring Board recommending the study continue without modification.

Summary

• Interim results from the ongoing Phase 3 clinical trial evaluating Ovaprene, an investigational monthly, hormone-free intravaginal contraceptive, were positive.
• The study's independent Data Safety Monitoring Board (DSMB) conducted a planned interim analysis focused on safety data and recommended the study continue without modification.
• No new safety or tolerability concerns were identified during the interim analysis.
• Approximately 9% of the women treated in the study had experienced a pregnancy at the time of the interim analysis, a rate consistent with the company's expectations based on prior pre-pivotal studies.
• Approximately 17% of participants discontinued the study due to vaginal odor, which was the most commonly reported product-related adverse event.
• Overall tolerability was favorable, and no serious safety concerns were identified.
• Participants who had completed the study reported they would be very likely or likely to use Ovaprene if it became available.
• The pivotal Phase 3 trial is a multicenter, single-arm, open-label study enrolling women aged 18-40 across five sites.
• As of the interim analysis, approximately 115 participants were ongoing or had completed the study, with a target enrollment of approximately 250 participants completing 12 months of use.
• The primary objective of the study is to assess the typical use pregnancy rate over 13 menstrual cycles, or the estimated Pearl Index for Ovaprene.
• Bayer has the right to obtain exclusive U.S. commercialization rights to Ovaprene following completion of the pivotal clinical trial, contingent on a $20 million payment to Dare Bioscience.
• Dare Bioscience may receive up to $310 million in commercial milestone payments, plus double-digit tiered royalties on net sales from Bayer.
• The potential $20 million payment and royalty payments are subject to a third-party minority interest under a royalty purchase agreement entered into in April 2024.

Sentiment

Score: 8

Explanation: The interim Phase 3 results for Ovaprene are positive, with the DSMB recommending continuation without modification and no new serious safety concerns. The pregnancy rate is consistent with expectations, and participants expressed high likelihood of use. The potential for significant commercialization payments and royalties from Bayer is a strong positive. The 17% discontinuation rate due to vaginal odor is a notable negative, but overall tolerability was favorable and no serious safety concerns were identified, indicating a strong positive outlook for the product's development.

Positives

• Positive interim safety and efficacy results were reported from the ongoing Phase 3 clinical trial of Ovaprene.
• The independent Data Safety Monitoring Board (DSMB) recommended the study continue without modification after reviewing safety data.
• No new safety or tolerability concerns were identified, and overall tolerability was favorable.
• The observed pregnancy rate of approximately 9% at the interim analysis was consistent with the company's expectations.
• Participants who completed the study indicated a high likelihood of using Ovaprene if it becomes available.
• Ovaprene has the potential to be a first-in-category, FDA-approved, hormone-free, monthly intravaginal contraceptive, addressing a significant unmet need in women's health.
• Dare Bioscience stands to receive substantial potential payments from Bayer, including a $20 million payment for commercial rights, up to $310 million in commercial milestone payments, and double-digit tiered royalties on net sales.

Negatives

• Approximately 17% of participants discontinued the study due to vaginal odor, which was the most commonly reported product-related adverse event.

Risks

• Positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies.
• Ability to develop, obtain FDA or foreign regulatory approval for, and commercialize product candidates and to do so on communicated timelines.
• Failure or delay in starting, conducting, and completing clinical trials of a product candidate.
• Ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of product candidates.
• Dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product.
• Risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with interpretation of or conclusions regarding data from clinical studies of product candidates.
• Development of a product candidate may require more clinical or nonclinical studies than anticipated, or that the duration of a study or number of study subjects must be significantly greater than anticipated.
• Ability to raise additional capital when and as needed to execute business strategy and continue as a going concern.
• Risk of delisting of common stock from Nasdaq.
• Effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on ability to raise additional capital or on operations, financial results and condition, and ability to achieve current plans and objectives.
• Reliance on third parties to commercialize XACIATO (clindamycin phosphate) vaginal gel 2% and future products, if any.
• Risk that the current regulatory pathway known as the FDA’s 505(b)(2) pathway for drug product approval in the U.S. is not available for a product candidate as anticipated.
• Ability to achieve the product development and other milestones required for it to receive payments under its subaward and grant agreements.
• The potential for termination of the subaward and grant agreements before additional payments are received.
• Limits on ability to sell stock under its equity line arrangement at times it may desire to raise additional capital.
• The loss of, or inability to attract, key personnel.
• Risk that developments by competitors make products or product candidates less competitive or obsolete.
• Difficulties establishing and sustaining relationships with development and/or commercial collaborators.
• Failure of products or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors.
• Ability to retain licensed rights to develop and commercialize a product or product candidate.
• Ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates.
• Ability to adequately protect or enforce its, or its licensors, intellectual property rights.
• The lack of patent protection for the active ingredients in certain product candidates which could expose its products to competition from other formulations using the same active ingredients.
• Product liability claims.
• Governmental investigations or actions relating to products or product candidates or the business activities of the company, its commercial collaborators or other third parties on which it relies.
• The impact of pharmaceutical industry regulation and health care legislation in the United States and internationally.
• Global trends toward health care cost containment.
• Cybersecurity incidents or similar events that compromise technology systems or those of third parties on which it relies and/or significantly disrupt business.
• Disputes or other developments concerning intellectual property rights.

Future Outlook

The company anticipates completing the Ovaprene Phase 3 study and conducting a final analysis of study endpoints, including the primary endpoint of pregnancy rate calculated using the Pearl Index. Ovaprene is expected to address a significant unmet need for effective, hormone-free birth control and potentially transform the contraceptive landscape. Bayer retains the right to obtain exclusive U.S. commercialization rights upon completion of the pivotal clinical trial, contingent on a $20 million payment.

Management Comments

• "We are encouraged by these interim results, which reinforce the potential of our hormone-free contraceptive candidate to provide women with a meaningful alternative to existing hormonal and non-hormonal methods."
• "With millions of women in the U.S. seeking effective, hormone-free birth control, Ovaprene has the potential to address a significant unmet need and transform the contraceptive landscape."
• "We look forward to the completion of the study and the final analysis of study endpoints, including the primary endpoint of pregnancy rate calculated using the Pearl Index."

Industry Context

The document highlights a significant unmet need for FDA-approved, hormone-free, monthly intravaginal contraceptives in the U.S. Ovaprene aims to be a first-in-category product, offering a novel alternative to existing hormonal and non-hormonal methods. This aligns with a broader industry trend towards developing diverse and less invasive contraceptive options that cater to a wider range of women's preferences and health needs.

Comparison to Industry Standards

• Ovaprene's interim pregnancy rate was approximately 9% per 100 women.
• According to the FDA's birth control guide, short-acting hormonal contraceptive methods (oral contraceptives, the patch, and the vaginal ring) have an expected pregnancy rate of 7 per 100 women.
• Male condoms have an expected pregnancy rate of 13 per 100 women.
• Diaphragms or sponges with spermicide have an expected pregnancy rate of 17 per 100 women.
• Ovaprene's interim 9% pregnancy rate is higher than short-acting hormonal methods (7%) but lower than male condoms (13%) and diaphragms/sponges with spermicide (17%).

Stakeholder Impact

• Shareholders: Positive interim results and the potential for a significant commercialization deal with Bayer could lead to increased shareholder value. However, risks related to clinical trial success, regulatory approval, and market acceptance remain.
• Patients/Consumers: Ovaprene offers a potential new hormone-free contraceptive option, addressing an unmet need for women seeking alternatives to hormonal methods, potentially improving access and choice.
• Employees: Continued progress in clinical trials and potential commercialization could provide job security and growth opportunities within the company.
• Bayer: If Bayer exercises its option, it gains exclusive U.S. commercialization rights to a novel contraceptive, potentially expanding its product portfolio in women's health and strengthening its market position.

Next Steps

• Completion of the ongoing Phase 3 clinical trial for Ovaprene.
• Final analysis of study endpoints, including the primary endpoint of pregnancy rate calculated using the Pearl Index.
• Bayer's decision on exercising its right to obtain exclusive U.S. commercialization rights for Ovaprene upon completion of the pivotal clinical trial, contingent on a $20 million payment.

Key Dates

Recommendation

Keywords

Ovaprene, contraceptive, hormone-free, intravaginal, Phase 3 clinical trial, womens health, Dare Bioscience, biopharmaceutical, FDA approval, Pearl Index, Bayer, clinical development, sexual health, vaginal health